MeiraGTx Holdings plc Excess Tax Benefit from Share-based Compensation, Operating Activities
MeiraGTx Holdings plc (MGTX) reported Excess Tax Benefit from Share-based Compensation, Operating Activities of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities · last filed 2022-03-10
- MeiraGTx Holdings plc excess tax benefit from share-based compensation, operating activities for the quarter ending 2021-12-31 was $0.00.
- MeiraGTx Holdings plc excess tax benefit from share-based compensation, operating activities for the quarter ending 2021-09-30 was $0.00.
- MeiraGTx Holdings plc excess tax benefit from share-based compensation, operating activities for the quarter ending 2021-06-30 was $0.00.
- MeiraGTx Holdings plc excess tax benefit from share-based compensation, operating activities for the quarter ending 2021-03-31 was $0.00.
- MeiraGTx Holdings plc excess tax benefit from share-based compensation, operating activities for fiscal 2021 was $0.00.
- MeiraGTx Holdings plc excess tax benefit from share-based compensation, operating activities for fiscal 2020 was $0.00.
- MeiraGTx Holdings plc excess tax benefit from share-based compensation, operating activities for fiscal 2019 was $0.00.
- MeiraGTx Holdings plc excess tax benefit from share-based compensation, operating activities for fiscal 2018 was $0.00.
| Period end | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 6 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $0.00 10-K · filed 2022-03-10 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $0.00 derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $0.00 derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $0.00 10-K · filed 2022-03-10 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | $0.00 derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | $0.00 derived: sum of 3 quarters · filed 2021-08-11 | $0.00 derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | $0.00 derived: sum of 3 quarters · filed 2021-05-11 | $0.00 derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-11 | $0.00 derived: sum of 3 quarters · filed 2021-03-11 | $0.00 10-K · filed 2021-03-11 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | $0.00 derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2020-08-06 | $0.00 derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-05-07 | $0.00 derived: sum of 3 quarters · filed 2020-05-07 | $0.00 derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $0.00 derived: sum of 2 quarters · filed 2020-03-11 | $0.00 derived: sum of 3 quarters · filed 2020-03-11 | $0.00 10-K · filed 2020-03-11 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 4 quarters · filed 2019-05-14 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-08 | $0.00 10-Q · filed 2019-08-07 | $0.00 derived: sum of 3 quarters · filed 2019-05-14 | $0.00 derived: sum of 4 quarters · filed 2019-05-14 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-14 | $0.00 derived: sum of 2 quarters · filed 2019-05-14 | $0.00 derived: sum of 3 quarters · filed 2019-05-14 | $0.00 derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $0.00 derived: sum of 2 quarters · filed 2019-03-26 | $0.00 derived: sum of 3 quarters · filed 2019-03-26 | $0.00 10-K · filed 2019-03-26 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-08 | $0.00 derived: sum of 2 quarters · filed 2018-11-08 | $0.00 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-08 | $0.00 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |